VAERS 2021 Database www.vaers.hhs.gov

Main Page | All 2021 Deaths | Videos
VAERS Updated: 11/12/2021
** VAERS DATABASE Last updated: November 12, 2021**
PLEASE CHECK BACK SOON
Download the files above while you wait.







Manufacturers

Total Manufacturer
46,870MODERNA
532GLAXOSMITHKLINE BIOLOGICALS
353PFIZER\BIONTECH
231MERCK & CO. INC.
221UNKNOWN MANUFACTURER
62SEQIRUS, INC.
25DYNAVAX TECHNOLOGIES CORPORATION
13EMERGENT BIOSOLUTIONS
12SANOFI PASTEUR
9NOVARTIS VACCINES AND DIAGNOSTICS
5PFIZER\WYETH
5PAXVAX
2TEVA PHARMACEUTICALS
2PROTEIN SCIENCES CORPORATION
1BERNA BIOTECH, LTD.
1INTERCELL AG
1CSL LIMITED

COVID19 Lot Number

VAX LOT Total
2S9CL1,906
1,575
289
IMM209286
252
236
229
s029456178
171
UT7065MA166
155
149
145
S034636133
107
U62828AA103
100
98
P10025327596
U6737AA85
UJ446AA79
78
78
59
57
4BH3254
4F47253
52
27656352
50
PP9L548
49TM346
42
40
38
MENVEO38
4F47237
R1B252M36
34
C5763AA30
93362229
25
300057A24
UNK24
22
CW311621
18
17
15
UH894AB15
3Y7NL12
R1B743M12
EJ168611
el128410
10
10
10
9
ARBA141A9
UNK9
8
UNK8
8
1F4EB8
Unknown7
7
No batch number6
5
5
UJ090AA5
5
5
4
4
4
UNK4
JEV18K95E4
UNK3
A115A3
Z127A3
3
3333324181073
2
2
2
TAR352
1
1
1
1
1
A739081
1
1
1
1
1
037K20A68,542
EL128447,700
133

Incidents per State

State Total
15,185
CA14,096
NY7,507
TX7,196
FL6,939
IN5,527
PA4,560
IL4,179
OH4,054
AZ3,856
MI3,771
NJ3,411
MA3,278
VA3,208
NC3,114
WA3,034
GA2,864
MD2,652
MN2,534
CO2,532
WI2,457
MO2,029
OR1,943
TN1,715
CT1,693
KY1,603
OK1,226
AL1,201
KS1,162
IA1,157
SC1,106
NM1,065
UT973
AR951
LA945
NE829
NV797
ME795
MT789
NH756
ID674
AK661
WV661
PR650
MS585
HI536
RI510
VT441
SD361
ND356
DE350
DC239
WY209
GU32
AS16
VI13
MP9
MH3
FM2
QM1
XB1

ID: 0951907
Sex: F
Age: 73
State: CO

Vax Date: 12/28/2020
Onset Date: 12/28/2020
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Administered with vaccine that has been refrozen; A spontaneous report was received from a nurse concerning a 73-year-old, female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and was administered with vaccine that has been refrozen. The patient's medical history was not provided. No relevant concomitant medications were reported. On 28 Dec 2020, the patient received their first of two planned doses of mRNA-1273 (Lot: 011J20A) intramuscularly in the left deltoid for prophylaxis of COVID-19 infection. On 31 Dec 2020, the nurse reported she had been storing the mRNA-1273 vaccines at -20 degrees Celsius but discovered that prior to the vaccine administration facility receiving the vaccines on 24 Dec 2020, they had been stored at 38.2 degrees Fahrenheit at another facility. No treatment information was provided. Action taken with mRNA-1273 in response to the event was not reported. The outcome of the event, administered with vaccine that has been refrozen, was considered resolved on 28 Dec 2020.; Reporter's Comments: This report refers to a case of Product storage error for mRNA-1273, lot # 025J20-2A. There were no reported AEs associated with this case of Product storage error.

Other Meds:

Current Illness:

ID: 0951908
Sex: F
Age: 55
State: CO

Vax Date: 12/28/2020
Onset Date: 12/28/2020
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Administered with vaccine that has been refrozen; A spontaneous report was received from a nurse concerning a 55-year-old, female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and was administered with vaccine that has been refrozen. The patient's medical history was not provided. No relevant concomitant medications were reported. On 28 Dec 2020, the patient received their first of two planned doses of mRNA-1273 (Lot: 025J20-2A) intramuscularly in the left deltoid for prophylaxis of COVID-19 infection. On 31 Dec 2020, the nurse reported she had been storing the mRNA-1273 vaccines at -20 degrees Celsius but discovered that prior to the vaccine administration facility receiving the vaccines on 24 Dec 2020, they had been stored at 38.2 degrees Fahrenheit at another facility. No treatment information was provided. Action taken with mRNA-1273 in response to the event was not reported. The outcome of the event, administered with vaccine that has been refrozen, was considered resolved on 28 Dec 2020.; Reporter's Comments: This report refers to a case of product storage error for mRNA-1273, lot # 025J20-2A. There were no reported adverse event associated with this case of product storage error.

Other Meds:

Current Illness:

ID: 0951909
Sex: F
Age: 38
State: RI

Vax Date: 12/30/2020
Onset Date: 12/30/2020
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Vaccine administered from vial which had been punctured for more than 6 hours; A spontaneous report was received from a nurse concerning a 38-year old, female patient who received Moderna's COVID-19 Vaccine (mRNA-1273) and experienced vaccine administered from vial which has been punctured for more than 6 hours. The patient's medical history was not provided. No relevant concomitant medications were reported. On 30 Dec 2020, prior to the onset of the event, the patient received their first of two planned doses of mRNA-1273 (Lot number: 026L20A) intramuscularly in the left deltoid for prophylaxis of COVID-19 infection. On 30 Dec 2020, between 8:00-11:00 am, the patient was administered a vaccine dose from a vial that had been punctured on 29 Dec 2020 at 6:00 pm. No treatment information was provided. Action taken with mRNA-1273 in response to the event was not reported. The event, vaccine administered from vial which had been punctured for more than 6 hours, was considered resolved on 30 Dec 2020.; Reporter's Comments: This report refers to a case of expired product administered for mRNA-1273 (Lot number: 026L20A). There were no reported AEs associated with this case.

Other Meds:

Current Illness:

ID: 0951910
Sex: F
Age:
State: CO

Vax Date: 12/28/2020
Onset Date: 12/28/2020
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Administered with vaccine that has been refrozen; A spontaneous report was received from a nurse concerning a 59-year-old, female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and was administered with vaccine that has been refrozen. The patient's medical history was not provided. No relevant concomitant medications were reported. On an undisclosed date, the County Health Department received the vaccine and stored the product at 38.2 degrees Fahrenheit. On 24 Dec 2020, the health care provider received the vaccine and stored the material at -20 degrees Celsius. The thawing procedure was followed prior to administration. On 28 Dec 2020, the patient received their first of two planned doses of mRNA-1273 (Lot number: 025J20-2A, Exp. date: 25 Feb 2021) intramuscularly in the left deltoid for prophylaxis of COVID-19 infection. On 31 Dec 2020, the nurse reported she had been storing the mRNA-1273 vaccines at -20 degrees Celsius but discovered that prior to the vaccine administration facility receiving the vaccines on 24 Dec 2020, they had been stored at 38.2 degrees Fahrenheit at another facility. No treatment information was provided. Action taken with mRNA-1273 in response to the event was not reported. The outcome of the event, administered with vaccine that has been refrozen, was considered resolved on 28 Dec 2020.; Reporter's Comments: This report refers to a case of Product storage error for mRNA-1273. There were no reported AEs associated with this case of product storage error.

Other Meds:

Current Illness:

ID: 0951911
Sex: M
Age: 60
State: CO

Vax Date: 12/28/2020
Onset Date: 12/28/2020
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Administered vaccine that has been refrozen; A spontaneous report was received from a nurse concerning a 60-year-old, male patient who received Moderna's COVID-19 vaccine (mRNA-1273) and was administered with vaccine that has been refrozen. The patient's medical history was not provided. No relevant concomitant medications were reported. On 28 Dec 2020, the patient received their first of two planned doses of mRNA-1273 (Lot: 025J20-2A) intramuscularly in the left deltoid for prophylaxis of COVID-19 infection. On 31 Dec 2020, the nurse reported she had been storing the mRNA-1273 vaccines at -20 degrees Celsius but discovered that prior to the vaccine administration facility receiving the vaccines on 24 Dec 2020, they had been stored at 38.2 degrees Fahrenheit at another facility. No treatment information was provided. Action taken with mRNA-1273 in response to the event was not reported. The outcome of the event, administered with vaccine that has been refrozen, was considered resolved on 28 Dec 2020.; Reporter's Comments: This case concerns a 60 year old, male patient. The patient's medical history is not provided. The event occurred on 28 Dec 2020, when the patient was given the first dose of the mRNA-1273 (Lot: 025J20-2A) . This report refers to a case of storage error where refrozen mRNA-1273 has been administered to the patient.

Other Meds:

Current Illness:

ID: 0951912
Sex: F
Age: 44
State: RI

Vax Date: 12/30/2020
Onset Date: 12/30/2020
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Vaccine administered from vial which has been punctured for more than 6 hours; A spontaneous report was received from a nurse concerning a 44-year-old, female patient who received Moderna's COVID-19 Vaccine (mRNA-1273) and experienced vaccine administered from vial which has been punctured for more than 6 hours. The patient's medical history not provided. No relevant concomitant medications were reported. On 30 Dec 2020, prior to the onset of the event, the patient received their first of two planned doses of mRNA-1273 (Lot number: 026L20A) intramuscularly in the left deltoid for prophylaxis of COVID-19 infection. On 30 Dec 2020, between 8:00-11:00 am, the patient was administered a vaccine dose from a vial that had been punctured on 29 Dec 2020 at 6:00 pm. No adverse events were reported. No treatment information was provided. Action taken with mRNA-1273 in response to the event was not reported. The event, vaccine administered from vial which has been punctured for more than 6 hours, was considered resolved on 30 Dec 2020.; Reporter's Comments: This case concerns a 44 year old, female patient. The patient's medical history is not provided. The patient experienced an unexpected event of vaccine administered from vial which has been punctured for more than 6 hours. The event occurred on 30 Dec 2020 during administration of the first dose of mRNA-1273 (Lot number: 026L20A). There were no reported adverse events. The sponsor considered the event as not related to mRNA-1273.

Other Meds:

Current Illness:

ID: 0951913
Sex: F
Age: 42
State: CO

Vax Date: 12/28/2020
Onset Date: 12/28/2020
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Administered with vaccine that has been refrozen; A spontaneous report was received from a nurse concerning a 42-year-old, female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and was administered with vaccine that has been refrozen. The patient's medical history was not provided. No relevant concomitant medications were reported. On 28 Dec 2020, the patient received their first of two planned doses of mRNA-1273 (Lot: 025J20-2A) intramuscularly in the right deltoid for prophylaxis of COVID-19 infection. On 31 Dec 2020, the nurse reported she had been storing the mRNA-1273 vaccines at -20 degrees Celsius but discovered that prior to the vaccine administration facility receiving the vaccines on 24 Dec 2020, they had been stored at 38.2 degrees Fahrenheit at another facility. No treatment information was provided. Action taken with mRNA-1273 in response to the event was not reported. The outcome of the event, administered with vaccine that has been refrozen, was considered resolved on 28 Dec 2020.; Reporter's Comments: This report refers to a case of Product storage error for mRNA-1273. There were no reported AEs associated with this case of product storage error.

Other Meds:

Current Illness:

ID: 0951914
Sex: F
Age: 44
State: RI

Vax Date: 12/30/2020
Onset Date: 12/30/2020
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Vaccine administered from vial which has been punctured for more than 6 hours; A spontaneous report was received from a nurse concerning a 44-years old, female patient who received Moderna's Covid-10 vaccine (mRNA-1273) and experienced vaccine administered from vial which has been punctured for more than 6 hours. The patient's medical history was not provided. No relevant concomitant medications were reported. On 30 Dec 2020, the patient received their first of two planned doses of mRNA-1273 (Lot number 026L20A) in the right deltoid intramuscularly for prophylaxis of COVID-19 infection. On 30 Dec 2020, between 8:00-11:00 am, the patient was administered a vaccine dose from a vial that had been punctured on 29 Dec 2020 at 6:00 pm. No adverse events were reported. No treatment information was provided. Action taken with mRNA-1273 in response to the events was not provided. The event, vaccine administered from vial which has been punctured for more than 6 hours, was resolved on 30 Dec 2020.; Reporter's Comments: This report refers to a case of expired product administered for mRNA-1273, lot # 026L20A. There were no reported AEs associated with this case of expired product administered.

Other Meds:

Current Illness:

ID: 0951915
Sex: F
Age: 41
State: CO

Vax Date: 12/28/2020
Onset Date: 12/28/2020
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Administered vaccine that was not stored in recommended teperature; A spontaneous report was received from a nurse concerning a 41-year-old, female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and was administered with vaccine that has been refrozen. The patient's medical history was not provided. No relevant concomitant medications were reported. On 28 Dec 2020, the patient received their first of two planned doses of mRNA-1273 (Lot: 025J20-2A) intramuscularly in the right deltoid for prophylaxis of COVID-19 infection. On 31 Dec 2020, the nurse reported she had been storing the mRNA-1273 vaccines at -20 degrees Celsius but discovered that prior to the vaccine administration facility receiving the vaccines on 24 Dec 2020, they had been stored at 38.2 degrees Fahrenheit at another facility. No treatment information was provided. Action taken with mRNA-1273 in response to the event was not reported. The outcome of the event, administered with vaccine that has been refrozen, was considered resolved on 28 Dec 2020.; Reporter's Comments: This report refers to a case of product storage error for mRNA-1273, lot # 025J20-2A. There were no reported AEs associated with this case of product storage error.

Other Meds:

Current Illness:

ID: 0951916
Sex: U
Age:
State:

Vax Date: 12/31/2020
Onset Date: 12/31/2020
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Some leakage from the hub of the side of needle; May not have received a full dose of the vaccine; A spontaneous report was received from a healthcare professional concerning a patient who received Moderna's COVID-19 Vaccine and who might not have received a full dose of the vaccine when there was some leakage from the hub side of the needle. The patient's medical history and concomitant product use were not provided/unknown by the reporter. On 31-Dec-2020 the patient received their first of two planned doses of mRNA-1273 intramuscularly for prophylaxis of COVID-19 infection. A physician reported that some leakage was observed from the hub of the side of a needle when the dose of vaccine was administered. The patient may not have received a full dose. Action taken with mRNA-1273 in response to the event was not reported. The outcome of the event, might not have received a full dose of the vaccine when there was some leakage from the hub side of the needle, was resolved on 31 Dec 2020.; Reporter's Comments: This report refers to a case of incorrect route of product leakage and incorrect dose administered for mRNA-1273, lot # unknown. There were no reported AEs associated with this case of product leakage and incorrect dose administered.

Other Meds:

Current Illness:

ID: 0951917
Sex: F
Age: 69
State: CO

Vax Date: 12/28/2020
Onset Date: 12/28/2020
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Administered with vaccine that has been refrozen; A spontaneous report was received from a nurse, concerning a 69-year-old, female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and was administered with vaccine that has been refrozen. The patient's medical history was not provided. No relevant concomitant medications were reported. On 28 Dec 2020, the patient received their first of two planned doses of mRNA-1273 (Lot: 025J20-2A) intramuscularly in the right deltoid for prophylaxis of COVID-19 infection. On 31 Dec 2020, the nurse reported she had been storing the mRNA-1273 vaccines at -20 degrees Celsius but discovered that prior to the vaccine administration facility receiving the vaccines on 24 Dec 2020, they had been stored at 38.2 degrees Fahrenheit at another facility. No treatment information was provided. Action taken with mRNA-1273 in response to the event was not reported. The outcome of the event, administered with vaccine that has been refrozen, was considered resolved on 28 Dec 2020.; Reporter's Comments: This case concerns a 69 year old, female patient. The patient's medical history is not provided. The event occurred on 28 Dec 2020, when the patient was given the first dose of the mRNA-1273 (Lot: 025J20-2A) . This report refers to a case of storage error where refrozen mRNA-1273 had been administered to the patient.

Other Meds:

Current Illness:

ID: 0951918
Sex: F
Age: 57
State: RI

Vax Date: 12/30/2020
Onset Date: 12/30/2020
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Vaccine administered from vial which has been punctured for more than 6 hours; A spontaneous report was received from a nurse concerning a 57-year-old female patient who received Moderna's COVID-19 Vaccine and experienced vaccine administered from vial which has been punctured for more than 6 hours. The patient's medical history was not provided. No relevant concomitant medications were reported. On 30 Dec 2020, the patient received their first of two planned doses of mRNA-1273 (Lot number: 026L20A) for prophylaxis of COVID-19 infection in the left deltoid. On 30 Dec 2020, between 8:00-11:00 am, the patient was administered a vaccine dose from a vial that had been punctured on 29 Dec 2020 at 6:00 pm. No adverse events were reported. No treatment information was provided. Action taken with mRNA-1273 in response to the event was not reported. The outcome of the event, vaccine administered from vial which has been punctured for more than 6 hours, was considered resolved on 30 Dec 2020; Reporter's Comments: This case concerns a 57-year-old female patient who received their first of two planned doses of mRNA-1273 (Lot 026L20A), reporting Expired product administered without any associated adverse events.

Other Meds:

Current Illness:

ID: 0951919
Sex: U
Age:
State: IL

Vax Date: 12/29/2020
Onset Date: 12/29/2020
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Administered to 17 year old; A spontaneous report was received from a healthcare facility staff member concerning a 17-year-old patient who received Moderna's COVID-19 vaccine (mRNA-1273) resulting in the event, administered vaccine to a 17 year old. The patient's medical history was not provided. No relevant concomitant medications were reported. On 29 Dec 2020, the patient received their first of two planned doses of mRNA-1273 intramuscularly for prophylaxis of COVID-19 infection. On 31 Dec 2020, the healthcare staff member reported the Moderna COVID vaccine was given to a 17 year old patient. No symptoms or treatments have been reported by the provider. Action taken with mRNA-1273 in response to the event was not reported. The outcome of the event, gave vaccine to a 17 year old, was considered resolved on 29 Dec 2020.; Reporter's Comments: This case concerns a 17 year old patient. The patient's medical history is not provided. The event occurred on 29 Dec 2020 during administration of the first dose of the mRNA-1273. This report refers to a case of medication error where mRNA-1273 has been administered to the patient of inappropriate age. There were no reported adverse reaction associated with this case.

Other Meds:

Current Illness:

ID: 0951920
Sex: M
Age: 64
State: RI

Vax Date: 12/30/2020
Onset Date: 12/30/2020
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Vaccine administered from vial which has been punctured for more than 6 hours; A spontaneous report was received from a nurse for a 64-year-old male patient who received Moderna's COVID-19 Vaccine and experienced vaccine administered from vial which has been punctured for more than 6 hours. The patient's medical history was not provided. No relevant concomitant medications were reported. On 30 Dec 2020, the patient received their first of two planned doses of mRNA-1273 (Lot number 026L20A) for prophylaxis of COVID-19 infection in the left deltoid. On 30 Dec 2020, between 8:00-11:00 am, the patient was administered a vaccine dose from a vial that had been punctured on 29 Dec 2020 at 6:00 pm. No adverse events were reported. No treatment information was provided.. Action taken with mRNA-1273 in response to the event was not reported. The outcome of the event, vaccine administered from vial which has been punctured for more than 6 hours, was recovered/resolved on 30 Dec 2020.; Reporter's Comments: This case concerns the 64-year old male patient who received Moderna's COVID-19 Vaccine (mRNA-1273) from a vial, which had been punctured for more than 6 hours. On 30 Dec 2020, between 8:00-11:00 am, the patient was administered a vaccine dose from a vial that had been punctured on 29 Dec 2020 at 6:00 pm. No adverse events were reported. Reported event is unlisted for COVID-19 Vaccine (mRNA-1273) and causality assessment was assessed as not applicable.

Other Meds:

Current Illness:

ID: 0951921
Sex: F
Age: 31
State: NY

Vax Date: 12/28/2020
Onset Date: 12/28/2020
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Redness in the injection spot; Injection spot not the right place; A spontaneous report was received from a nurse concerning a 31-years old female patient, who was also a physician, who received the Moderna COVID-19 Vaccine (mRNA-1273) and experienced product administered at inappropriate injection site and injection site erythema. The patient's medical history was not provided. No relevant concomitant medications were provided. The patient received her first of two planned doses of mRNA-1273 vaccine (batch number 039K20-2A) on 28 Dec 2020 intramuscularly in the left arm for prophylaxis of COVID-19 infection and experienced product administered at inappropriate injection site when the shot was given below her deltoid. On 29 Dec 2020, the patient noticed redness at the injection site. Treatment information was provided. Action taken in response to the events were not reported. The outcome of the event, injection site erythema, was not resolved. The outcome of the event, product administered at inappropriate injection site, was resolved on 28 Dec 2020.; Reporter's Comments: This case concerns a 31 year-old female, who experienced a non-serious expected event of injection site erythema and product administered at inappropriate site. The event of injection site erythema occurred 1 day after first dose of mRNA-1273, lot # 039K20-2A. No treatment was administered for injection site erythema. Based on the current available information and temporal association between the use of the product and onset of the event, a causal relationship cannot be excluded. There was no reported AE associated with the case of product administered at inappropriate site.

Other Meds:

Current Illness:

ID: 0951922
Sex: F
Age: 56
State: CO

Vax Date: 12/28/2020
Onset Date: 12/28/2020
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Administered with vaccine that has been refrozen; A spontaneous report was received from a nurse concerning a 56-year-old, female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and was administered with vaccine that has been refrozen. The patient's medical history was not provided. No relevant concomitant medications were reported. On 28 Dec 2020, the patient received their first of two planned doses of mRNA-1273 (Lot: 025J20-2A) intramuscularly in the right deltoid for prophylaxis of COVID-19 infection. On 31 Dec 2020, the nurse reported she had been storing the mRNA-1273 vaccines at -20 degrees Celsius but discovered that prior to the vaccine administration facility receiving the vaccines on 24 Dec 2020, they had been stored at 38.2 degrees Fahrenheit at another facility. No treatment information was provided. Action taken with mRNA-1273 in response to the event was not reported. The outcome of the event, administered with vaccine that has been refrozen, was considered resolved on 28 Dec 2020.; Reporter's Comments: This report refers to a case of Product storage error for mRNA-1273. There were no reported AEs associated with this case of product storage error.

Other Meds:

Current Illness:

ID: 0951923
Sex: F
Age: 63
State: CO

Vax Date: 12/28/2020
Onset Date: 12/28/2020
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Administered a vaccine that has been refrozen; A spontaneous report was received from a nurse concerning a 63-year-old, female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and was administered with vaccine that has been refrozen. The patient's medical history was not provided. No relevant concomitant medications were reported. On 28 Dec 2020, the patient received their first of two planned doses of mRNA-1273 (Lot: 025J20-2A) intramuscularly in the right deltoid for prophylaxis of COVID-19 infection. On 31 Dec 2020, the nurse reported she had been storing the mRNA-1273 vaccines at -20 degrees Celsius but discovered that prior to the vaccine administration facility receiving the vaccines on 24 Dec 2020, they had been stored at 38.2 degrees Fahrenheit at another facility. No treatment information was provided. Action taken with mRNA-1273 in response to the event was not reported. The outcome of the event, administered with vaccine that has been refrozen, was considered resolved on 28 Dec 2020. .; Reporter's Comments: This report refers to a case of administered a vaccine that has been refrozen for mRNA-1273, lot # 025J20-2A. There were no reported adverse events associated with this case of administered a vaccine that has been refrozen.

Other Meds:

Current Illness:

ID: 0951924
Sex: F
Age: 42
State: CO

Vax Date: 12/28/2020
Onset Date: 12/28/2020
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Administered with vaccine that has been refrozen; A spontaneous report was received from a nurse concerning a 42-year-old, female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and was administered with vaccine that has been refrozen. The patient's medical history was not provided. No relevant concomitant medications were reported. On 28 Dec 2020, the patient received their first of two planned doses of mRNA-1273 (Lot: 025J20-2A) intramuscularly in the left deltoid for prophylaxis of COVID-19 infection. On 31 Dec 2020, the nurse reported she had been storing the mRNA-1273 vaccines at -20 degrees Celsius but discovered that prior to the vaccine administration facility receiving the vaccines on 24 Dec 2020, they had been stored at 38.2 degrees Fahrenheit at another facility. No treatment information was provided. Action taken with mRNA-1273 in response to the event was not reported. The outcome of the event, administered with vaccine that has been refrozen, was considered resolved on 28 Dec 2020.; Reporter's Comments: This report refers to a case of Product storage error for mRNA-1273. There were no reported AEs associated with this case of product storage error.

Other Meds:

Current Illness:

ID: 0951925
Sex: F
Age: 46
State: CO

Vax Date: 12/28/2020
Onset Date: 12/28/2020
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Administered a vaccine that has been refrozen; A spontaneous report was received from a nurse concerning a 47-year-old, female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and was administered with vaccine that has been refrozen. The patient's medical history was not provided. No relevant concomitant medications were reported. On 28 Dec 2020, the patient received their first of two planned doses of mRNA-1273 (Lot: 025J20-2A) intramuscularly in the left deltoid for prophylaxis of COVID-19 infection. On 31 Dec 2020, the nurse reported she had been storing the mRNA-1273 vaccines at -20 degrees Celsius but discovered that prior to the vaccine administration facility receiving the vaccines on 24 Dec 2020, they had been stored at 38.2 degrees Fahrenheit at another facility. No treatment information was provided. Action taken with mRNA-1273 in response to the event was not reported. The outcome of the event, administered with vaccine that has been refrozen, was considered resolved on 28 Dec 2020.; Reporter's Comments: This report refers to a case of Product storage error for mRNA-1273. There were no reported AEs associated with this case of product storage error.

Other Meds:

Current Illness:

ID: 0951926
Sex: F
Age: 56
State: CO

Vax Date: 12/28/2020
Onset Date: 12/28/2020
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Administered a vaccine that has been refrozen; A spontaneous report was received from a nurse concerning a 56-year-old, female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and was administered with vaccine that has been refrozen. The patient's medical history was not provided. No relevant concomitant medications were reported. On 28 Dec 2020, the patient received their first of two planned doses of mRNA-1273 (Lot: 025J20-2A) intramuscularly in the right deltoid for prophylaxis of COVID-19 infection. On 31 Dec 2020, the nurse reported she had been storing the mRNA-1273 vaccines at -20 degrees Celsius but discovered that prior to the vaccine administration facility receiving the vaccines on 24 Dec 2020, they had been stored at 38.2 degrees Fahrenheit at another facility. No treatment information was provided. Action taken with mRNA-1273 in response to the event was not reported. The outcome of the event, administered with vaccine that has been refrozen, was considered resolved on 28 Dec 2020.; Reporter's Comments: This report refers to a case of Product storage error for mRNA-1273. There were no reported AEs associated with this case of product storage error.

Other Meds:

Current Illness:

ID: 0951927
Sex: F
Age:
State: AK

Vax Date:
Onset Date:
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Administered vaccine to 17 year old; A spontaneous report was received from a nurse concerning a 17 year old, female, patient who received Moderna's COVID-19 vaccine (mRNA-1273) resulting in the event, administered vaccine to a 17 year old. The patient's medical history was not provided. No relevant concomitant medications were reported. On an unknown date, the patient received their first of two planned doses of mRNA-1273 intramuscularly for prophylaxis of COVID-19 infection. The nurse reported the Moderna COVID vaccine was given to a 17 year old patient on an unknown date. No treatment information was provided. Action taken with mRNA-1273 in response to the event was not reported. The outcome of the event, administered vaccine to a 17 year old, was considered resolved.; Reporter's Comments: This case concerns a 17-year-old female patient who received their first of two planned doses of mRNA-1273 (Lot unknown), reporting Product administered to patient of inappropriate age without any associated adverse events.

Other Meds:

Current Illness:

ID: 0951928
Sex: U
Age:
State:

Vax Date:
Onset Date:
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: While administering the vaccine "quite a bit" leaked out; A spontaneous report was received from a pharmacist, concerning a patient who received Moderna's COVID-19 vaccine (mRNA-1273) and while administering the vaccine "quite a bit" leaked out. The patient's medical history was not provided. No relevant concomitant medications were reported. On an unknown date, the patient received their first of two planned doses of mRNA-1273 intramuscularly for prophylaxis of COVID-19 infection. On an unknown date, the reporter stated that a vaccine administrator did not attach the needle to the syringe and while administering the vaccine "quite a bit" leaked out and some was administered. Treatment information was not provided. Action taken with mRNA-1273 in response to the event was not reported. The events, while administering the vaccine "quite a bit" leaked out, was considered resolved.; Reporter's Comments: This case concerns a patient who received their first of two planned doses of mRNA-1273 (Lot unknown), reporting Incorrect dose administered without any associated adverse events.

Other Meds:

Current Illness:

ID: 0951929
Sex: F
Age: 14
State: KS

Vax Date: 12/30/2020
Onset Date: 12/30/2020
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Moderna COVID-19 vaccine was administered to a 14 year old girl; A spontaneous report was received from a consumer concerning a 14-yeasr-old female patient who received Moderna's COVID-19 Vaccine and experienced the event, inappropriate age at vaccine administration. The patient's medical history and concomitant product use were not provided/unknown by the reporter. On 30 Dec 2020 the patient received their first of two planned doses of mRNA-1273 (lot number either 025J20-219 or 025J20-214) intramuscularly for prophylaxis of COVID-19 infection, and the vaccine was administered to a 14-years old patient. Action taken with mRNA-1273 in response to the events was not provided. The outcome of the event, inappropriate age at vaccine administration, was resolved on 30 Dec 2020.; Reporter's Comments: This case concerns a 14-year-old female patient who received their first of two planned doses of mRNA-1273 (Lot 025J20-219/4), reporting Product administration to patient of inappropriate age without any associated adverse events.

Other Meds:

Current Illness:

ID: 0951930
Sex: F
Age:
State: IL

Vax Date:
Onset Date:
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Some of it leaked out and was enough to get her shirt wet, maybe she got 1/3 of the dose; A spontaneous report was received from a pharmacist concerning a female patient who received Moderna's Covid-19 vaccine (mRNA-1273) and experienced incomplete dose administered. The patient's medical history was not provided. Concomitant product use was not provided by the reporter. On an undisclosed date, the patient received her first of two planned doses of mRNA-1273 (Lot number not provided) intramuscularly for prophylaxis of COVID-19 infection. Enough product leaked out to get her shirt wet. The pharmacist reported that the patient received maybe one-third of the dose. Treatment for the event was not provided. Action taken with mRNA-1273 in response to the events was not provided. The event, incomplete dose administered, was considered resolved. Action taken with mRNA-1273 in response to the events was not provided.; Reporter's Comments: This case concerns a female patient who received their first of two planned doses of mRNA-1273 (Lot unknown), reporting Incorrect dose administered without any associated adverse events.

Other Meds:

Current Illness:

ID: 0951931
Sex: F
Age:
State:

Vax Date: 12/30/2020
Onset Date: 12/30/2020
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Received vaccine below the deltoid in the bicep muscle; A spontaneous report was received from a female consumer who received Moderna's COVID-19 vaccine (mRNA-1273) and received the vaccine below the deltoid in the bicep muscle. The patient's medical history was not provided. No relevant concomitant medications were reported. On 30 Dec 2020, the patient received their first of two planned doses of mRNA-1273 intramuscularly for prophylaxis of COVID-19 infection. The patient reported that she typically received vaccines in her deltoid muscle but received the mRNA-1273 vaccine below the deltoid, in the bicep muscle. No treatment information was provided. Action taken with mRNA-1273 in response to the event was not reported. The event, received vaccine below the deltoid in the bicep muscle, was considered resolved on 30 Dec 2020.; Reporter's Comments: This case concerns a female patient who received their first of two planned doses of mRNA-1273 (Lot unknown), reporting Product administered at inappropriate site without any associated adverse events.

Other Meds:

Current Illness:

ID: 0951932
Sex: F
Age: 53
State: CO

Vax Date: 12/28/2020
Onset Date: 12/28/2020
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Administered a vaccine that has been refrozen; A spontaneous report was received from a nurse concerning a 53-year-old, female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and was administered with vaccine that has been refrozen. The patient's medical history was not provided. No relevant concomitant medications were reported. On 28 Dec 2020, the patient received their first of two planned doses of mRNA-1273 (Lot: 025J20-2A) intramuscularly in the left deltoid for prophylaxis of COVID-19 infection. On 31 Dec 2020, the nurse reported she had been storing the mRNA-1273 vaccines at -20 degrees Celsius but discovered that prior to the vaccine administration facility receiving the vaccines on 24 Dec 2020, they had been stored at 38.2 degrees Fahrenheit at another facility. No treatment information was provided. Action taken with mRNA-1273 in response to the event was not reported. The outcome of the event, administered with vaccine that has been refrozen, was considered resolved on 28 Dec 2020.; Reporter's Comments: This report refers to a case 53-year-old, female administered a vaccine that has been refrozen for mRNA-1273, lot # 025J20-2A. There were no reported adverse events associated with this case of administered a vaccine that has been refrozen.

Other Meds:

Current Illness:

ID: 0951933
Sex: F
Age: 65
State: CO

Vax Date: 12/28/2020
Onset Date: 12/28/2020
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Administered a vaccine that has been refrozen; A spontaneous report was received from a nurse concerning a 65-year-old, female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and was administered with vaccine that has been refrozen. The patient's medical history was not provided. No relevant concomitant medications were reported. On 28 Dec 2020, the patient received their first of two planned doses of mRNA-1273 (Lot: 025J20-2A) intramuscularly in the left deltoid for prophylaxis of COVID-19 infection. On 31 Dec 2020, the nurse reported she had been storing the mRNA-1273 vaccines at -20 degrees Celsius but discovered that prior to the vaccine administration facility receiving the vaccines on 24 Dec 2020, they had been stored at 38.2 degrees Fahrenheit at another facility. No treatment information was provided. Action taken with mRNA-1273 in response to the event was not reported. The outcome of the event, administered with vaccine that has been refrozen, was considered resolved on 28 Dec 2020.; Reporter's Comments: This report refers to a case of Product storage error for mRNA-1273, lot # 025J20-2A. There were no reported AEs associated with this case of Product storage error.

Other Meds:

Current Illness:

ID: 0951934
Sex: F
Age: 49
State: CO

Vax Date: 12/28/2020
Onset Date: 12/28/2020
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Administered vaccine that has been refrozen; A spontaneous report was received from a nurse concerning a 49-year-old, female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and was administered with vaccine that has been refrozen. The patient's medical history was not provided. No relevant concomitant medications were reported. On 28 Dec 2020, the patient received their first of two planned doses of mRNA-1273 (Lot: 025J20-2A) intramuscularly in the right deltoid for prophylaxis of COVID-19 infection. On 31 Dec 2020, the nurse reported she had been storing the mRNA-1273 vaccines at -20 degrees Celsius but discovered that prior to the vaccine administration facility receiving the vaccines on 24 Dec 2020, they had been stored at 38.2 degrees Fahrenheit at another facility. No treatment information was provided. Action taken with mRNA-1273 in response to the event was not reported. The outcome of the event, administered with vaccine that has been refrozen, was considered resolved on 28 Dec 2020.; Reporter's Comments: This case concerns a 49 year old, female patient. The patient's medical history is not provided. The event occurred on 28 Dec 2020, when the patient was given the first dose of the mRNA-1273 (Lot: 025J20-2A) . This report refers to a case of storage error where refrozen mRNA-1273 had been administered to the patient.

Other Meds:

Current Illness:

ID: 0951935
Sex: M
Age: 75
State: CO

Vax Date: 12/28/2020
Onset Date: 12/28/2020
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Administered a vaccine that has been refrozen; A spontaneous report was received from a nurse concerning a 75-year-old, male patient who received Moderna's COVID-19 vaccine (mRNA-1273) and was administered with vaccine that has been refrozen. The patient's medical history was not provided. No relevant concomitant medications were reported. On 28 Dec 2020, the patient received their first of two planned doses of mRNA-1273 (Lot: 025J20-2A) intramuscularly in the right deltoid for prophylaxis of COVID-19 infection. On 31 Dec 2020, the nurse reported she had been storing the mRNA-1273 vaccines at -20 degrees Celsius but discovered that prior to the vaccine administration facility receiving the vaccines on 24 Dec 2020, they had been stored at 38.2 degrees Fahrenheit at another facility. No treatment information was provided. Action taken with mRNA-1273 in response to the event was not reported. The outcome of the event, administered with vaccine that has been refrozen, was considered resolved on 28 Dec 2020.; Reporter's Comments: This report refers to a case of a 75-year-old, male patient who was administered a vaccine that has been refrozen for mRNA-1273, lot # 025J20-2A. There were no reported adverse events associated with this case of administered a vaccine that has been refrozen.

Other Meds:

Current Illness:

ID: 0951936
Sex: F
Age: 58
State: CO

Vax Date: 12/28/2020
Onset Date: 12/28/2020
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Administered a vaccine that has been refrozen; A spontaneous report was received from a nurse concerning a 58-year-old, female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and was administered with vaccine that has been refrozen. The patient's medical history was not provided. No relevant concomitant medications were reported. On 28 Dec 2020, the patient received their first of two planned doses of mRNA-1273 (Lot: 025J20-2A) intramuscularly in the left deltoid for prophylaxis of COVID-19 infection. On 31 Dec 2020, the nurse reported she had been storing the mRNA-1273 vaccines at -20 degrees Celsius but discovered that prior to the vaccine administration facility receiving the vaccines on 24 Dec 2020, they had been stored at 38.2 degrees Fahrenheit at another facility. No treatment information was provided. Action taken with mRNA-1273 in response to the event was not reported. The outcome of the event, administered with vaccine that has been refrozen, was considered resolved on 28 Dec 2020.; Reporter's Comments: This case concerns a 58 year old female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and was administered with vaccine that has been refrozen. This report refers to a case of product storage error for mRNA-1273, lot # 025J20-2A. There were no reported AEs associated with this case of product storage error.

Other Meds:

Current Illness:

ID: 0951937
Sex: F
Age: 22
State: CO

Vax Date: 12/28/2020
Onset Date: 12/28/2020
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Administered with vaccine that has been refrozen; A spontaneous report was received from a nurse concerning a 22-year-old, female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and was administered with vaccine that has been refrozen. The patient's medical history was not provided. No relevant concomitant medications were reported. On 28 Dec 2020, the patient received their first of two planned doses of mRNA-1273 (Lot: 025J20-2A) intramuscularly in the left deltoid for prophylaxis of COVID-19 infection. On 31 Dec 2020, the nurse reported she had been storing the mRNA-1273 vaccines at -20 degrees Celsius but discovered that prior to the vaccine administration facility receiving the vaccines on 24 Dec 2020, they had been stored at 38.2 degrees Fahrenheit at another facility. No treatment information was provided. Action taken with mRNA-1273 in response to the event was not reported. The outcome of the event, administered with vaccine that has been refrozen, was considered resolved on 28 Dec 2020.; Reporter's Comments: This case concerns a 22 year old, female patient. The patient's medical history is not provided. The event occurred on 28 Dec 2020, when the patient was given the first dose of the mRNA-1273 (Lot: 025J20-2A). This report refers to a case of storage error where refrozen mRNA-1273 has been administered to the patient.

Other Meds:

Current Illness:

ID: 0951938
Sex: F
Age: 33
State: CO

Vax Date: 12/28/2020
Onset Date: 12/28/2020
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Administered with vaccine that has been refrozen; A spontaneous report was received from a nurse concerning a 33-year-old, female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and was administered with vaccine that has been refrozen. The patient's medical history was not provided. No relevant concomitant medications were reported. On 28 Dec 2020, the patient received their first of two planned doses of mRNA-1273 (Lot: 025J20-2A) intramuscularly in the left deltoid for prophylaxis of COVID-19 infection. On 31 Dec 2020, the nurse reported she had been storing the mRNA-1273 vaccines at -20 degrees Celsius but discovered that prior to the vaccine administration facility receiving the vaccines on 24 Dec 2020, they had been stored at 38.2 degrees Fahrenheit at another facility. No treatment information was provided. Action taken with mRNA-1273 in response to the event was not reported. The outcome of the event, administered with vaccine that has been refrozen, was considered resolved on 28 Dec 2020.; Reporter's Comments: This report refers to a case of a 33-year-old, female patient who was administered a vaccine that has been refrozen for mRNA-1273, lot # 025J20-2A. There were no reported adverse events associated with this case of administered a vaccine that has been refrozen.

Other Meds:

Current Illness:

ID: 0951939
Sex: U
Age:
State: NM

Vax Date:
Onset Date:
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Vaccine was stored at -20 Degrees F so outside of the Temperature range; A spontaneous report was received from a pharmacist concerning a patient who received Moderna's COVID-19 vaccine (mRNA-1273) that was stored at -20 degrees F, so outside of the temperature range. The patient's medical history was not provided. No relevant concomitant medications were reported. On an unknown date, the patient received their first of two planned doses of mRNA-1273 intramuscularly for prophylaxis of COVID-19 infection. The reporter stated the COVID-19 vaccine was stored at -20 degrees Fahrenheit; outside of the recommended temperature range. No treatment information was provided. Action taken with mRNA-1273 in response to the event was not reported. The event, vaccine that was stored at -20 degrees F so outside of the temperature range, was considered resolved.; Reporter's Comments: This case concerns a patient who received their first of two planned doses of mRNA-1273 (Lot unknown), reporting Product storage error without any associated adverse events.

Other Meds:

Current Illness:

ID: 0951940
Sex: U
Age:
State: NM

Vax Date:
Onset Date:
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Vaccine was stored at -20 Degrees F so outside of the Temperature range; A spontaneous report was received from a pharmacist concerning a patient who received Moderna's COVID-19 vaccine (mRNA-1273) that was stored at -20 degrees F, so outside of the temperature range. The patient's medical history was not provided. No relevant concomitant medications were reported. On an unknown date, the patient received their first of two planned doses of mRNA-1273 intramuscularly for prophylaxis of COVID-19 infection. The reporter stated the COVID-19 vaccine was stored at -20 degrees Fahrenheit; outside of the recommended temperature range. No treatment information was provided. Action taken with mRNA-1273 in response to the event was not reported. The event, vaccine that was stored at -20 degrees F so outside of the temperature range, was considered resolved.; Reporter's Comments: This case concerns a patient who received their first of two planned doses of mRNA-1273 (Lot unknown), reporting Product storage error without any associated adverse events.

Other Meds:

Current Illness:

ID: 0951941
Sex: U
Age:
State: NM

Vax Date:
Onset Date:
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Vaccine was stored at -20 Degrees F so outside of the Temperature range; A spontaneous report was received from a pharmacist concerning a patient who received Moderna's COVID-19 vaccine (mRNA-1273) that was stored at -20 degrees F, so outside of the temperature range. The patient's medical history was not provided. No relevant concomitant medications were reported. On an unknown date, the patient received their first of two planned doses of mRNA-1273 intramuscularly for prophylaxis of COVID-19 infection. The reporter stated the COVID-19 vaccine was stored at -20 degrees Fahrenheit; outside of the recommended temperature range. No treatment information was provided. Action taken with mRNA-1273 in response to the event was not reported. The event, vaccine that was stored at -20 degrees F so outside of the temperature range, was considered resolved.; Reporter's Comments: This case concerns a patient who received their first of two planned doses of mRNA-1273 (Lot unknown), reporting Product storage error without any associated adverse events.

Other Meds:

Current Illness:

ID: 0951942
Sex: U
Age:
State: NM

Vax Date:
Onset Date:
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Vaccine was stored at -20 Degrees F so outside of the Temperature range; A spontaneous report was received from a pharmacist concerning a patient who received Moderna's COVID-19 vaccine (mRNA-1273) that was stored at -20 degrees F, so outside of the temperature range. The patient's medical history was not provided. No relevant concomitant medications were reported. On an unknown date, the patient received their first of two planned doses of mRNA-1273 intramuscularly for prophylaxis of COVID-19 infection. The reporter stated the COVID-19 vaccine was stored at -20 degrees Fahrenheit; outside of the recommended temperature range. No treatment information was provided. Action taken with mRNA-1273 in response to the event was not reported. The event, vaccine that was stored at -20 degrees F so outside of the temperature range, was considered resolved.; Reporter's Comments: This case concerns a patient who received their first of two planned doses of mRNA-1273 (Lot unknown), reporting Product storage error without any associated adverse events.

Other Meds:

Current Illness:

ID: 0951943
Sex: U
Age:
State: NM

Vax Date:
Onset Date:
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Vaccine was stored at -20 Degrees F so outside of the Temperature range; A spontaneous report was received from a pharmacist concerning a patient who received Moderna's COVID-19 vaccine (mRNA-1273) that was stored at -20 degrees F, so outside of the temperature range. The patient's medical history was not provided. No relevant concomitant medications were reported. On an unknown date, the patient received their first of two planned doses of mRNA-1273 intramuscularly for prophylaxis of COVID-19 infection. The reporter stated the COVID-19 vaccine was stored at -20 degrees Fahrenheit; outside of the recommended temperature range. No treatment information was provided. Action taken with mRNA-1273 in response to the event was not reported. The event, vaccine that was stored at -20 degrees F so outside of the temperature range, was considered resolved.; Reporter's Comments: This case concerns a patient who received their first of two planned doses of mRNA-1273 (Lot unknown), reporting Product storage error without any associated adverse events.

Other Meds:

Current Illness:

ID: 0951944
Sex: U
Age:
State: NM

Vax Date:
Onset Date:
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Vaccine was stored at -20 Degrees F so outside of the Temperature range; A spontaneous report was received from a pharmacist concerning a patient who received Moderna's COVID-19 vaccine (mRNA-1273) that was stored at -20 degrees F, so outside of the temperature range. The patient's medical history was not provided. No relevant concomitant medications were reported. On an unknown date, the patient received their first of two planned doses of mRNA-1273 intramuscularly for prophylaxis of COVID-19 infection. The reporter stated the COVID-19 vaccine was stored at -20 degrees Fahrenheit; outside of the recommended temperature range. No treatment information was provided. Action taken with mRNA-1273 in response to the event was not reported. The event, vaccine that was stored at -20 degrees F so outside of the temperature range, was considered resolved.; Reporter's Comments: This case concerns a patient who received their first of two planned doses of mRNA-1273 (Lot unknown), reporting Product storage error without any associated adverse events.

Other Meds:

Current Illness:

ID: 0951945
Sex: U
Age:
State: NM

Vax Date:
Onset Date:
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Vaccine was stored at -20 Degrees F so outside of the Temperature range; A spontaneous report was received from a pharmacist concerning a patient who received Moderna's COVID-19 vaccine (mRNA-1273) that was stored at -20 degrees F, so outside of the temperature range. The patient's medical history was not provided. No relevant concomitant medications were reported. On an unknown date, the patient received their first of two planned doses of mRNA-1273 intramuscularly for prophylaxis of COVID-19 infection. The reporter stated the COVID-19 vaccine was stored at -20 degrees Fahrenheit; outside of the recommended temperature range. No treatment information was provided. Action taken with mRNA-1273 in response to the event was not reported. The event, vaccine that was stored at -20 degrees F so outside of the temperature range, was considered resolved.; Reporter's Comments: This case concerns a patient who received their first of two planned doses of mRNA-1273 (Lot unknown), reporting Product storage error without any associated adverse events.

Other Meds:

Current Illness:

ID: 0951946
Sex: U
Age:
State: NM

Vax Date:
Onset Date:
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Vaccine was stored at -20 Degrees F so outside of the Temperature range; A spontaneous report was received from a pharmacist concerning a patient who received Moderna's COVID-19 vaccine (mRNA-1273) that was stored at -20 degrees F, so outside of the temperature range. The patient's medical history was not provided. No relevant concomitant medications were reported. On an unknown date, the patient received their first of two planned doses of mRNA-1273 intramuscularly for prophylaxis of COVID-19 infection. The reporter stated the COVID-19 vaccine was stored at -20 degrees Fahrenheit; outside of the recommended temperature range. No treatment information was provided. Action taken with mRNA-1273 in response to the event was not reported. The event, vaccine that was stored at -20 degrees F so outside of the temperature range, was considered resolved.; Reporter's Comments: This case concerns a patient who received their first of two planned doses of mRNA-1273 (Lot unknown), reporting Product storage error without any associated adverse events.

Other Meds:

Current Illness:

ID: 0951947
Sex: U
Age:
State: NM

Vax Date:
Onset Date:
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Vaccine was stored at -20 Degrees F so outside of the Temperature range; A spontaneous report was received from a pharmacist concerning a patient who received Moderna's COVID-19 vaccine (mRNA-1273) that was stored at -20 degrees F, so outside of the temperature range. The patient's medical history was not provided. No relevant concomitant medications were reported. On an unknown date, the patient received their first of two planned doses of mRNA-1273 intramuscularly for prophylaxis of COVID-19 infection. The reporter stated the COVID-19 vaccine was stored at -20 degrees Fahrenheit; outside of the recommended temperature range. No treatment information was provided. Action taken with mRNA-1273 in response to the event was not reported. The event, vaccine that was stored at -20 degrees F so outside of the temperature range, was considered resolved.; Reporter's Comments: This case concerns a patient who received their first of two planned doses of mRNA-1273 (Lot unknown), reporting Product storage error without any associated adverse events.

Other Meds:

Current Illness:

ID: 0951948
Sex: F
Age: 36
State: RI

Vax Date: 12/30/2020
Onset Date: 12/30/2020
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Vaccine administered from vial which had been punctured for more than 6 hours; A spontaneous report was received from a nurse concerning a 36-year-old female patient who received Moderna's COVID-19 Vaccine (mRNA-1273) from a vial which had been punctured for more than 6 hours. The patient's medical history was not provided. No relevant concomitant medications were reported. On 30 Dec 2020, prior to the onset of the event, the patient received their first of two planned doses of mRNA-1273 (Lot number: 026L20A) intramuscularly in the left deltoid for prophylaxis of COVID-19 infection. On 30 Dec 2020, between 8:00-11:00 am, the patient was administered a vaccine dose from a vial that had been punctured on 29 Dec 2020 at 6:00 pm. No adverse events were reported. No treatment information was provided. Action taken with mRNA-1273 in response to the event was not reported. The event, administered vaccine from vial which has been punctured for more than 6 hours, was considered resolved on 30 Dec 2020.; Reporter's Comments: This case concerns a 36-year-old patient who received their first of two planned doses of mRNA-1273 (Lot 026L20A), reporting vaccine administered from a vial which has been punctured for more than 6 hours without any associated adverse events.

Other Meds:

Current Illness:

ID: 0951949
Sex: M
Age:
State: FL

Vax Date: 12/29/2020
Onset Date: 12/29/2020
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Gave the patient a vaccine and it leaked out; syringe leak/product leak; A spontaneous report was received from a pharmacist concerning a male patient who received Moderna's COVID-19 Vaccine (mRNA-1273) and experienced vaccine leaked out down his arm while being administered. The patient's medical history was not provided. No relevant concomitant medications were reported. On 29 Dec 2020, the patient received their first of two planned doses of mRNA-1273 (Lot 011J20A) intramuscularly in the arm for prophylaxis of COVID-19 infection. During the vaccine administration, the vaccine leaked out down the patient's arm. Action taken with mRNA-1273 in response to the event was not reported. The outcome of the event, vaccine leaked out down his arm while being administered, was considered resolved on 29 Dec 2020.; Reporter's Comments: This case concerns a male patient. The patient's medical history is not provided. The patient experienced the unexpected event of vaccine leaked out down his arm during the administration of the first dose of the mRNA-1273 (Lot 011J20A) on 29 Dec2020. This report refers to a case of Product administration error for mRNA-1273, lot # 011J20A.

Other Meds:

Current Illness:

ID: 0951950
Sex: F
Age:
State: WI

Vax Date: 01/04/2021
Onset Date: 01/04/2021
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Received a partial dose; A spontaneous report was received from a nurse concerning a female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and received a partial dose. The patient's medical history was not provided. No relevant concomitant medications were reported. On 04 Jan 2021, the patient received their first of two planned doses of mRNA-1273 intramuscularly for prophylaxis of COVID-19 infection. On 04 Jan 2021, during vaccine administration, the patient received a partial dose. The nurse reported the syringe was not fully attached to the hub and there was leakage. The patient received a partial dose, but how much she received was unknown. No treatment information provided. Action taken with mRNA-1273 in response to the event was not reported. The event, received a partial dose, was considered resolved.; Reporter's Comments: This report refers to a case of incorrect dose administered for mRNA-1273, lot # unknown. There were no reported AEs associated with this case of incorrect dose administered.

Other Meds:

Current Illness:

ID: 0951951
Sex: F
Age: 68
State: NV

Vax Date: 12/28/2020
Onset Date: 12/28/2020
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: No available appointment for second dose of vaccine; Sore arm; A spontaneous report was received from a 58 year old female consumer who received Moderna's COVID-19 vaccine (mRNA-1273) and there was no available appointment for second dose of vaccine and developed a sore arm. The patient's medical history included hypertension. Concomitant medications reported included unspecified hypertension medications. On 28 Dec 2020, the patient received their first of two planned doses of mRNA-1273 (Lot number: 025J20-2A) intramuscularly for prophylaxis of COVID-19 infection. On 28 Dec 2020, after vaccine administration, the patient was a little sore for a day and a half. On 31 Dec 2020, the patient reported that her second dose of the vaccine should be on 25 Jan 2021 and that there was no available appointment for her. It had been recommended to the patient that she receive her second dose within 36 days of the first dose. No treatment was administered for the events. Action taken with mRNA-1273 in response to the events was unknown. The event, developed a sore arm, was considered resolved on 29 Dec 2020. The event, no available appointment for second dose of vaccine was considered resolved on 31 Dec 2020.; Reporter's Comments: This case concerns a 58 year-old female, who experienced a non-serious expected event of pain in extremity and Inappropriate schedule of Product administration. The event occurred soon after the first dose of mRNA-1273, lot # 025J20-2A. Based on the current available information and temporal association between the use of the product and the start date of the event, for the event of pain in extremity a causal relationship cannot be excluded. There was no reported AE associated with this case of Inappropriate schedule of Product administration.

Other Meds:

Current Illness: Hypertension

ID: 0951952
Sex: U
Age:
State: TX

Vax Date: 12/31/2020
Onset Date: 12/31/2020
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Patient received vaccine past the six hour expiration date; A spontaneous report was received from a nurse concerning a patient who received Moderna's COVID-19 vaccine (mRNA-1273) and the patient received vaccine past the six hour expiration date. The patient's medical history was not provided. No relevant concomitant medications were reported. On 31 Dec 2020, the patient received their first of two planned doses of mRNA-1273 (Lot number: 025L20A) intramuscularly for prophylaxis of COVID-19 infection. On 31 Dec 2020, the patient received an mRNA-1273 vaccine dose that was past the six-hour expiration date. The first dose from the vial had been administered more than six hours before the patient received their dose. The patient did not experience any adverse events. Treatment information was not provided. Action taken with mRNA-1273 in response to the event was not reported. The event, patient received vaccine past the six hour expiration date, was considered resolved on 31 Dec 2020.; Reporter's Comments: This report refers to a case of out of specification product use for mRNA-1273, lot # 025L20a. There were no reported AEs associated with this case of out of specification product use.

Other Meds:

Current Illness:

ID: 0951953
Sex: U
Age:
State: TX

Vax Date: 12/31/2020
Onset Date: 12/31/2020
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Patient received vaccine past the six hour expiration date; A spontaneous report was received from a nurse concerning a patient who received MODERNA's COVID-19 vaccine (mRNA-1273) and the patient received vaccine past the six hour expiration date. The patient's medical history was not provided. No relevant concomitant medications were reported. On 31 Dec 2020, the patient received their first of two planned doses of mRNA-1273 (Lot number: 025L20A) intramuscularly for prophylaxis of COVID-19 infection. On 31 Dec 2020, the patient received an mRNA-1273 vaccine dose that was past the six-hour expiration date. The first dose from the vial had been administered more than six hours before the patient received their dose. The patient did not experience any adverse events. Treatment information was not provided. Action taken with mRNA-1273 in response to the event was not reported. The event, patient received vaccine past the six hour expiration date, was considered resolved on 31 Dec 2020.; Reporter's Comments: This report refers to a case of out of specification product use for mRNA-1273, lot # 025L20A. There were no reported adverse events associated with this case of out of specification product use.

Other Meds:

Current Illness:

ID: 0951954
Sex: U
Age:
State: TX

Vax Date: 01/01/2021
Onset Date: 01/01/2021
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Patient received vaccine past the six hour expiration date; A spontaneous report was received from a nurse concerning a patient who received Moderna's COVID-19 vaccine (mRNA-1273) and patient received vaccine past the six hour expiration date. The patient's medical history was not provided. No relevant concomitant medications were reported. On 01 Jan 2021, the patient received their first of two planned doses of mRNA-1273 (Lot number: 025L20A) intramuscularly for prophylaxis of COVID-19 infection. On 01 Jan 2021, the patient received an mRNA-1273 vaccine dose that was past the six-hour expiration date. The first dose from the vial had been administered more than six hours before the patient received their dose. The patient did not experience any adverse events. Treatment information was not provided. Action taken with mRNA-1273 in response to the event was not reported. The event, patient received vaccine past the six hour expiration date, was considered resolved on 01 Jan 2021.; Reporter's Comments: This case concerns a patient of unknown age and gender. The patient's medical history is not provided. The event occurred on 01 Jan 2021, when the patient received the first dose of the mRNA-1273 (Lot number: 025L20A), past the six hour expiration date. This report refers to a case of Product administration error where mRNA-1273(Lot number: 025L20A) was given past 6 hours of opening the vial. There were no reported adverse events associated with this case.

Other Meds:

Current Illness:

ID: 0951955
Sex: M
Age: 46
State: TX

Vax Date: 12/31/2020
Onset Date: 12/31/2020
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Patient received vaccine past the six hour expiration date; A spontaneous report was received from a nurse concerning a 46-year-old, male, patient who received Moderna's COVID-19 vaccine (mRNA-1273) and patient received vaccine past the six hour expiration date. The patient's medical history was not provided. No relevant concomitant medications were reported. On 31 Dec 2020, the patient received their first of two planned doses of mRNA-1273 (Lot number: 025L20A) intramuscularly for prophylaxis of COVID-19 infection. On 31 Dec 2020, the patient received an mRNA-1273 vaccine dose that was past the six-hour expiration date. The first dose from the vial had been administered more than six hours before the patient received his dose. The patient did not experience any adverse events. Treatment information was not provided. Action taken with mRNA-1273 in response to the event was not reported. The event, patient received vaccine past the six hour expiration date, was considered resolved on 31 Dec 2020.; Reporter's Comments: This case concerns a 46 year old, male patient. The patient's medical history is not provided. The event occurred on 31 Dec 2020, when the patient was given the first dose of the mRNA-1273 (Lot number: 025L20A), past the six hour expiration date. This report refers to a case of Product administration error where mRNA-1273(Lot number: 025L20A) was given past 6 hours of opening the vial. There were no reported AEs associated with this case.

Other Meds:

Current Illness:

ID: 0951956
Sex: U
Age:
State: MA

Vax Date:
Onset Date:
Rec V Date: 01/18/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Vaccine given from vial outside of 6 hour storage window; A spontaneous report was received from a physician concerning a patient who received Moderna's COVID-19 Vaccine (mRNA-1273) and who experienced expired product administered. The patient's medical history was not provided. No relevant concomitant medications were reported. On an undisclosed date, a vial containing mRNA-1273 was punctured and stored refrigerated for over six hours. On an unknown date, prior to the onset of the event, the patient received their first of two planned doses of mRNA-1273 intramuscularly for prophylaxis of COVID-19 infection from the vial that had been punctured over six hours ago, and the patient experienced expired product administered. Action taken with mRNA-1273 in response to the event was not reported. The event, expired product administered, was considered resolved on an unknown date.; Reporter's Comments: This case concerns a patient of unknown age and gender. The patient's medical history is not provided. This report refers to a case of out of specification product use for mRNA-1273 on an unknown date.

Other Meds:

Current Illness:

Total 2021 VAERS Injuries: 134,999

Page last modified: 14 December 2021 10:42pm